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ABSTRACT
The glucocorticoid and progesterone receptors (GR
and PR) are closely related members of the steroid re-
ceptor family. Despite sharing similar structural and
functional characteristics; the cognate hormones
display very distinct physiological responses. In
mammary epithelial cells, PR activation is associ-
ated with the incidence and progression of breast
cancer, whereas the GR is related to growth sup-
pression and differentiation. Despite their pharma-
cological relevance, only a few studies have com-
pared GR and PR activities in the same system.
Using a PR+/GR+ breast cancer cell line, here
we report that either glucocorticoid-free or dex-
amethasone (DEX)-activated GR inhibits progestin-
dependent gene expression associated to epithelial-
mesenchymal-transition and cell proliferation. When
both receptors are activated with their cognate hor-
mones, PR and GR can form part of the same com-
plex according to co-immunoprecipitation, quantita-
tive microscopy and sequential ChIP experiments.
Moreover, genome-wide studies in cells treated with
either DEX or R5020, revealed the presence of sev-
eral regions co-bound by both receptors. Surpris-
ingly, GR also binds novel genomic sites in cells
treated with R5020 alone. This progestin-induced GR
binding was enriched in REL DNA motifs and located
close to genes coding for chromatin remodelers. Un-
derstanding GR behavior in the context of progestin-
dependent breast cancer could provide new targets
for tumor therapy.
INTRODUCTION
Steroid hormones regulate a wide range of physiological
processes through their binding to ligand-regulated tran-
scription factors, including the estrogen receptor (ER), pro-
gesterone receptor (PR) and the glucocorticoid receptor
(GR). In particular, their combined action modulates the
development and differentiation of the mammary gland
(1). Consistently with this pivotal role, their activity is also
linked to breast cancer (2–4).
In ER+/PR+ breast cancer cells, increased circulating
levels of progestins and estrogens and/or over-expression
of their receptors lead to an uncontrolled cellular division
(5,6). While the proliferating role of estrogens is well under-
stood, widespread controversy exists regarding progestin
actions. Although progestins are involved in driving cell
proliferation, thus favoring breast cancer development, they
may be safely and effectively used in treating ER-dependent
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breast cancer (6,7). In contrast, glucocorticoids are known
to be involved in cellular differentiation in the post-natal
mammary gland (8,9), while in proliferating cells––along
pregnancy or in tumor cells––these hormones induce the
expression of cell-cycle inhibitors (8) and mesenchymal-to-
epithelial transition (10).
The functional crosstalk between GR and ER has
been widely studied (7,11–14). Glucocorticoids exert an
antagonistic effect on estrogen-dependent cell growth in
ER+/GR+ breast and uterine carcinoma cells (15,16) and
reduce MCF-7 cell proliferation by more than 30% com-
pared to untreated cells (17). In contrast to ER and GR
studies, little is known about the influence of GR on PR
transcriptional activity. These receptors share many similar
structural characteristics, although the regulation of their
quaternary structure may differ (18). With a 90% sequence
identity between their DNA binding domains (DBD), they
have similar capacity to bind their responsive elements in
chromatin. PR and GR are also able to interact with the
same members of the p160 cofactor family [with histone
acetyltransferase activity (19)] and with similar chromatin
remodelers [e.g. SWI/SNF, P/CAF and/or SAGA (20,21)].
Even with a 55% sequence identity between their ligand
binding domains, some steroids are able to bind both PR
and GR (22), suggesting a potential crosstalk between the
two pathways. However, in cells expressing both GR and
PR, glucocorticoids and progestins exert very distinct and,
in some situations opposite physiological responses. For ex-
ample, the association of progestins with the incidence and
progression of breast cancer contrasts with the growth sup-
pressive action of glucocorticoids in ER+/PR+ mammary
cancer cells (23–25). Moreover, while GR and PR can both
activate and repress target genes (26), the relevant features
that make these receptors and their actions different are still
unknown.
To date, only a few studies have been performed compar-
ing the GR and PR responses in the same system (25,27–
29), which is limited by the tissue-specific expression pat-
tern of both receptors. Particularly, microarray analysis in
the T47D/A1–2 cell line, which expresses similar amounts
of both receptors, revealed that the two hormones differ-
entially regulate overlapping but also distinct sets of genes
(25).
A potential molecular interaction between GR and PR
has also remained largely unexplored. In the GR+ MDA-
MB-231 breast cancer cell line, transfection with PR has
shown that corticosterone, the endogenous glucocorticoid,
induces progesterone-like morphological changes (30). This
suggests that glucocorticoids can regulate cell morphology
through the PR regulated pathway. On the other hand, little
information is available on the effect of progesterone treat-
ment on GR activity in breast cancer cell models (12,31).
Understanding how these receptors behave in breast can-
cer is relevant not only from a physiological but also from
a pharmacological perspective. Due to the extensive use of
glucocorticoids as a palliative option for the treatment of
breast cancer and the activation of GR by synthetic pro-
gestins used in hormone replacement therapies, we decided
to focus our study on the influence of GR on the PR-
dependent breast cancer cell proliferation and dedifferen-
tiation (31). We used the T47D/A1-2 human breast can-
cer cell line that expresses comparable levels of GR and
PR (27).
We found that GR expression, even in the absence of
glucocorticoids, inhibits PR-dependent cell proliferation
through the modulation of key PR-target genes. When GR
is activated by the synthetic glucocorticoid dexamethasone
(DEX), the antagonistic effect increases and most likely
involves the formation of GR-PR protein complexes. PR
and GR ChIP-seq analyses reveal overlapping binding sites
genome-wide and sequential-ChIP on key enhancer sites
confirms co-recruitment to shared sites. Unexpectedly, we
found that glucocorticoid-free GR can bind to a pattern of
unique binding sites upon stimulation with the PR-agonist
R5020, which could explain, at least in part, the interference
with the PR-dependent transcriptional response.
MATERIALS AND METHODS
Cell culture and treatments
T47D-WT breast cancer cells carrying one stably integrated
copy of the luciferase reporter gene driven by the MMTV
promoter (32) and its derivative clone T47D/A1-2 that also
expresses a functional full length rGR (27) were routinely
grown in Dulbecco’s Modified Eagle’s medium (DMEM,
Thermo Fisher Scientific). MCF-7L cells were kindly pro-
vided by Carol Lange although originally obtained from C.
Kent Osborne (Baylor College of Medicine, Houston, TX,
USA) (33). These cells were maintained in Dulbecco’s Mod-
ification of Eagle’s Medium supplemented with 10% fetal
bovine serum (FBS), 100 U/ml penicillin, 100 mg/ml strep-
tomycin and 1.4 U/ml Insulin (Novo Nordisk® Pharma).
For experiments, all cells were plated in DMEM medium
without phenol red supplemented with 10% dextran-coated
charcoal-treated FBS (DCC/FBS) and 48-h later medium
was replaced by fresh medium without serum. After 24 h
in serum-free conditions, cells were incubated with R5020
(Sigma) 10 nM and/or DEX (Sigma) 10 nM for different
lengths of times at 37◦C according to each experiment.
RNA interference experiments
siRNA of GR from Dharmacon (ON-TARGETplus
SMARTpool Rat Nr3c1 siRNA L-089504-02-0005 or
SMARTpool siGENOME Human NR3C1 siRNA M-
003424-03-0005) was transfected into the T47D/A1-2 or
MCF-7L cells, respectively using Lipofectamine 2000 (In-
vitrogen). After 48 h, the medium was replaced by fresh
medium without serum. After one day in serum-free condi-
tions, cells were incubated with R5020 10 nM, and/or DEX
10 nM or vehicle (ethanol) for different times at 37◦C. The
downregulation of GR expression was determined by west-
ern blot using GR antibody (MA1-510, Thermo Fisher Sci-
entific).
Cell proliferation assay
T47D-WT and T47D/A1-2 cells transfected with control
or GR siRNAs were cultured as described above. Cells (1 ×
104) were plated in a 96-well plate in the presence or absence
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BrdU Colorimetric assay (Roche) was performed accord-
ing to the manufacturer’s instructions. Figures show the per-
centage increase of proliferation in the presence versus ab-
sence of R5020 or DEX. The experiments were performed
in quintuplicate.
Cell-cycle analysis
The effects of R5020 or DEX on cell cycle distribu-
tion were examined using PI flow cytometry assay. T47D-
WT; T47D/A1-2 and MCF-7L cells were seeded in
DMEM medium without phenol red supplemented with
10% DCC/FBS. After an overnight incubation, cells were
treated with R5020 10 nM and/or DEX 10 nM for 18 h.
Detached and adherent cells were collected and fixed in
70% ethanol in phosphate-buffered saline (PBS) at −20◦C
overnight. Cells were then resuspended in PBS containing
20 g/ml PI and 100 g/ml RNAse and incubated for 30
min at 37◦C in the dark. Samples were then analyzed on
a BD FACSAria II flow cytometer (BD Biosciences) using
BD FACSDiva6.0 software.
Flow cytometry
For cell surface marker analysis, cells were washed once
with PBS and then harvested with 0.05% trypsin/0.025%
EDTA. Detached cells were washed with PBS contain-
ing 0.5% BSA (wash buffer) and resuspended in the wash
buffer (106 cells/100 l). Combinations of fluorochrome-
conjugated monoclonal antibodies obtained from BD Bio-
sciences against human CD44 (APC; cat. # 560890) and
CD24 (PE; cat. #560991), were added to the cell suspen-
sion at concentrations recommended by the manufacturer
and incubated at 4◦C in the dark for 30 min. The labeled
cells were washed in wash buffer and immediately were sub-
jected to fluorescence-activated cell sorting analysis using
BD FACS Calibur (34).
Subcellular fractions separation and Co-IP assay
T47D/A1-2 cells were incubated for 1 h with R5020 and
DEX. For subcellular fraction separation, cells were cen-
trifuged for 5 min at 2000 rpm and washed with ice-cold
PBS buffer. Cells were then incubated in 300 l of hypo-
tonic buffer (10 mM Tris–HCl pH 6.7; 0.2 mM MgCl2;
1 mM EGTA; protease inhibitors) for 5 min on an ice-
water bath and lysed by douncing homogenization. Sam-
ples were centrifuged at 1500 rpm for 10 min at 4◦C and
supernatants were referred as cytoplasmic fraction. Pellets
were washed twice in ice-cold PBS buffer, resuspended in
250 l of lysis buffer (20 mM Tris–HCl pH 6.7; 70 mM
NaCl; 10% glycerol; 1% Triton X-100; 0.5% Nonidet P-40;
protease inhibitor), and incubated on ice-water bath for 30
min. Samples were sonicated three times for 10 s at 20% out-
put with a Branson 450 Sonifier. After the addition of 0.5 M
NaCl, the incubation was continued for additional 30 min.
Samples were centrifuged at 12 000 rpm for 5 min at 4◦C,
and supernatants were referred to as nuclear fraction. For
co-immunoprecipitation assay (Co-IP), nuclear fraction (1
mg protein) was precleared at 4◦C with Dynabeads® Pro-
tein G (Thermo Fisher Scientific) for 1 h before incubating
overnight at 4◦C with anti-PR antibody (H-190, sc-7208,
Santa Cruz Biotechnology) or an unspecific control anti-
body (normal rabbit IgG, sc-2017, Santa Cruz Biotechnol-
ogy). Complexes were incubated with Dynabeads® Protein
G (Thermo Fisher Scientific) for 3 h at 4◦C. The beads were
washed by rocking for 5 min in nuclear lysis buffer and the
immunoprecipitated (IP) proteins were eluted by boiling in
sodium dodecyl sulfate-sample buffer. Inputs and IPs were
analyzed by western blot using PR antibody (H-190, sc-
7208, Santa Cruz Biotechnology) and GR antibody (MA1-
510, Thermo Fisher Scientific).
Subcellular localization and cross-correlation analysis
T47D-WT cells were transfected with 2 g of peGFP-
PR (kindly provided by Dr Carol Lange, Departments of
Medicine and Pharmacology, University of Minnesota Ma-
sonic Cancer Center, Minneapolis, MN, USA) (35) and
pmCherry-GR (36) and incubated with vehicle, R5020 10
nM and/or DEX 10 nM for at least 1 h. Images were
obtained in a FV1000 confocal laser scanning microscope
(Olympus), with an Olympus UPlanSApo 60× oil immer-
sion objective (NA = 1.35). eGFP and mCherry were ex-
cited with a multi-line Ar laser at 488 nm and a He-Ne green
laser at 543 nm (average power at the sample, 700 nW),
respectively. Fluorescence was detected with a photomul-
tiplier set in the pseudo photon-counting detection mode.
The pixel size was set at 83 nm. Analysis of subcellular dis-
tribution was performed using ImageJ (NIH, USA) soft-
ware. The nucleus and the cytoplasm regions were manually
selected for each individual cell and the nucleus/cytoplasm
intensity ratio was then calculated (n = 19–26). Cross-
brightness (Bcc) measurements were done as previously de-
scribed (36). Briefly, for each studied cell a time stack of 200
images (256 × 256 pixels) was taken in the microscope setup
mentioned above, setting the pixel dwell time to 10 s. The
frame time was 0.9 s. Each stack was further analyzed using
the ‘N&B’ routine of the ‘GLOBALS for Images’ software
developed at the Laboratory for Fluorescence Dynamics
(University of California, Irvine, CA, USA). Bcc was deter-
mined following the procedures described by Digman et al.
(37) for every pixel of the nucleus. This parameter was calcu-
lated from the cross-variance between eGFP and mCherry
channels normalized by the product of their mean intensi-
ties. Therefore, Bcc describes cross-correlated fluctuations in
both channels and acquires positive values when both fluo-
rescent molecules are present in the same complex. An av-
erage Bcc was determined from the pixels of the nucleus and
this analysis was performed for 50 cells in each condition.
ChIP-seq
All ChIP-seq experiments were performed with the follow-
ing conditions of culture and treatments: T47D/A1-2 cells
were grown 48 h in DMEM without phenol red supple-
mented with 10% DCC/FBS and synchronized in G0/G1
by 24 h of serum starvation. R5020 or DEX was added to
the medium at 10 nM, and cells were harvested after 1 h
of hormone treatment. ChIP-DNA was purified and sub-
jected to deep sequencing using the Solexa Genome Ana-
lyzer (Illumina, San Diego, CA, USA). Replicates for ChIP-
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1 h were obtained from a previous publication (38) (Sup-
plementary Table S1). The raw sequence reads were aligned
and processed as previously described (39,40). In brief, se-
quence reads were aligned to human (UCSC hg19) genome
using Bowtie (41). Only sequences uniquely aligned with
≤1 mismatch were retained. Post-alignment processing of
sequence reads included in silico extension and signal nor-
malization based on the number of million mapped reads.
Reads were extended to a final length equal to MACS frag-
ment size estimation (42), and only unique reads were re-
tained. For signal normalization, the number of reads map-
ping to each base in the genome was counted using the
genomeCoverageBed command from BedTools (43). Pro-
cessed files were visualized in the UCSC genome browser
(44). Transcription factor enrichment sites were detected
with MACS (42) using default parameters and a P-value of
1E-10. A control dataset derived by sequencing input DNA
samples was used to define a background model. Heatmap
and aggregation plots: To compute the heatmap and aggre-
gation (averageogram) plots we divided the bed files con-
taining the regions of interest (spanning ±3 Kb from the
center of the TF peaks for the averageograms, or ±6 Kb in
the case of the heatmaps) in 100 bp bins. The coverage signal
from the GR and PR aligned read bed files for the differ-
ent cell lines (PR: T47D-A1/2 and wild-type; GR: T47D-
A1/2) and conditions (i.e. hormone treated or not) was ob-
tained for each bin using the coverageBed command from
BedTools (43). For quantile normalization of the results ob-
tained from each condition (defined by the combination of
TF, hormone treatment and cell line), we produced 100 bp
bins across all the peaks called in each condition and calcu-
lated the signal coverage of the ChIP-seq dataset in the same
condition in which the peaks were called. The 95th quantile
obtained from the binned peaks in each TF and cell line
was used to adjust the bin values obtained for the aggrega-
tion plots. The heatmaps were produced with Cluster3 soft-
ware (45) and plotted using Treeview (46). Motif Discovery:
De novo motif discovery was performed with HOMER (47)
using a window of 200 bp around peaks and setting mo-
tifs length to 8, 10, 12 and 14 bp. The best scoring motif
was chosen from each analysis to represent the DNA bind-
ing domain for each of the factors profiled. The co-enriched
motifs obtained for the different lengths were independently
analyzed for consistency of the results and manually curated
to exclude redundant motifs. The top scoring motifs, ranked
by P-value, are shown in each case. Matching DNA bind-
ing motifs were associated to the de novo recovered matrix
when the HOMER score was 0.65 or higher. In Supplemen-
tary Figures S3A and 7B, the percentage of occurrence of
the motifs are the defaults calculated by the HOMER soft-
ware, and represent the number (expressed as percentage) of
GR- or PR-bound regions (under the corresponding stim-
uli) in which the motif is found. As a reference, the number
of background regions (defined by default in the HOMER
software) in which the same motif is found, are shown sep-
arated by a bar. For the bar-plots showing the occurrence
of de novo recovered motifs at selected regions (Figures 2B
and 6D), the de novo motif matrices recovered by HOMER
were added to the list of known motifs used by HOMER,
and the motif analysis was re-run using this file. The re-
sults then show the number of selected regions (expressed
as percentage) in which the corresponding motif was found
in the regions analyzed, and the corresponding background
regions used. Functional annotation: Functional annotation
of genes associated with TF binding regions was performed
using GREAT with default settings (48).
ChIP and sequential ChIP assays in cultured cells
ChIP assays were performed as described (49) using anti-
PR antibody (H-190, sc-7208, Santa Cruz Biotechnology),
a combination of anti-GR antibodies (P-20, sc-1002 and M-
20, sc-1004, Santa Cruz Biotechnology) or a non-specific
control antibody. Quantification of ChIP was performed by
real-time polymerase chain reaction (PCR) using Applied
Biosystems StepOnePlus™ (Thermo Fisher Scientific). The
fold enrichment of the target sequence in the IP DNA com-
pared with the input (Ref) fractions was calculated us-
ing the comparative Ct (the number of cycles required to
reach a threshold concentration) method with the equation
2Ct(IP) - Ct(Ref) and referred as % of input. The sequences of
the PCR primers are available upon request. For sequential
ChIP or re-ChIP assays, immunoprecipitation was washed
sequentially as described previously (49). Complexes were
eluted with 10 mM Dithiothreitol (DTT) for 30 min at 37◦C,
diluted 50 times with dilution buffer and then subjected to
a second round of immunoprecipitation with the indicated
antibodies or with IgG.
RNA extraction and RT–PCR
Total RNA was prepared, and cDNA was generated as
previously described (50). Quantification of gene prod-
ucts was performed by real-time PCR. Each value cal-
culated using the standard curve method was corrected
by the human Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) and expressed as relative RNA abundance over
time zero. Primer sequences are available on request.
Statistical analysis
Results were expressed as means ± S.D., as it is indicated
in the figure legends. Student’s t-test and one-way or two-
way ANOVA tests followed by Tukey’s post-hoc test or Bon-
ferroni post-test were used to detect significant differences
among treatments. Statistical analyses were performed us-
ing GraphPad Prism-5 (GraphPad Software). Differences
were considered statistically significant if P ≤ 0.05.
RESULTS
GR expression affects progestin-mediated cell proliferation
and dedifferentiation
To test GR influence on progestin action, we compared
two PR+ cell line models: the T47D-MTVL (WT) cells
and its derivative clone T47D/A1-2, which also expresses
a functional full length GR (27,51). Even though T47D-
MTVL (WT) cells have been characterized as PR+ and
GR low (32,52), in our hands GR levels in these cells are
undetectable by Western blot (Supplementary Figure S1A)
and, more importantly, glucocorticoids fail to activate the







 Fac de Agronom
ia user on 10 O
ctober 2019
Nucleic Acids Research, 2019 5
Thus, we will consider T47D-MTVL (WT) cells as ‘GR
functionally negative’ hereafter.
Given the known association of progestins with the in-
cidence and progression of breast cancer and the inhibi-
tion of cell growth exerted by glucocorticoids (8,12,53), we
first evaluated whether GR expression and/or activation af-
fected progestin-dependent cell proliferation in breast can-
cer cells. Hormone-dependent cell proliferation was as-
sessed by quantifying BrdU incorporation in either T47D-
WT or T47D/A1-2 cells. We observed a clear progestin-
dependent increase in proliferation of T47D-WT cells (3-
fold versus untreated cells) upon 14 h addition of the syn-
thetic PR agonist, R5020 (Figure 1A, upper panel and
Supplementary Figure S1C, left panel). Intriguingly, no
progestin-dependent BrdU incorporation was detected in
T47D/A1-2 cells treated with R5020 for 14 h (Supplemen-
tary Figure S1C, right panel). However, by extending hor-
mone treatment to 18 h we observed an increase in prolifera-
tion (∼2-fold), indicating a slower growing-rate of this GR+
cell line compared to WT (Figure 1A, lower panel and Sup-
plementary Figure S1C, right panel). Consistently, the pro-
gestin effect was significantly impaired when the synthetic
glucocorticoid DEX was added (Figure 1A lower panel).
The inhibitory effect is GR-dependent, as only T47D/A1-2
cells respond to DEX. The glucocorticoid alone had no ef-
fect compared with control (Figure 1A). These results were
confirmed by FACS analysis performed in both cell lines
stained with propidium iodide. The percentage of cells ac-
cumulated in S phase was significantly lower in T47D/A1-
2 cells treated with R5020 compared to T47D-WT (14.7
versus 21.8%, respectively) (Supplementary Figure S2A) re-
inforcing the idea that GR expression affects progestin-
dependent cell proliferation. Moreover, DEX alone did not
affect S phase accumulation in T47D/A1-2 cells (6.9 ver-
sus 7% in untreated cells) but inhibited R5020 mediated ac-
tion (12.7 versus 15.2% in R5020 treated cells, Supplemen-
tary Figure S2B).
To test whether the presence of GR is solely responsible
for the observed inhibitory effect on progestin-dependent
cell proliferation, we monitored cell proliferation upon
transfection of T47D/A1-2 cells with small interfering
RNA (siRNA) for GR (Figure 1B). GR depletion lead
to WT levels of BrdU incorporation in T47D/A1-2 cells
treated with the progestin alone. Also, GR knock-down
partially reverted DEX mediated inhibition in cells treated
with both hormones (Figure 1B, right panel). In conclusion,
while GR expression seems to impair progestin-dependent
cell proliferation in mammary tumor epithelial cells, GR ac-
tivation with DEX completely abrogates it.
Next, we asked whether GR can also affect the progestin-
dependent dedifferentiation process occurring in T47D-WT
cells (34). For this purpose, we evaluated the hormone-
dependent expression patterns of the dedifferentiation
markers CD44 and CD24 by flow cytometry and quan-
tified the proportion of CD44high/CD24low population, a
hallmark of dedifferentiation. While the CD44high/CD24low
phenotype was lower in T47D/A1-2 cells compared to
T47D-WT in the absence of any stimuli (1.7 versus 3.2%, re-
spectively), R5020 treatment significantly increased the per-
centage to 9.2% in T47D-WT cells (Figure 1C) but only to
3.0% in the T47D/A1-2 cells. These results indicate that GR
presence impairs cell dedifferentiation. Moreover, as shown
in Figure 1D, GR activation with DEX significantly di-
minished both the percentage of CD44high/CD24low in un-
treated cells or treated with R5020 to values comparable to
T47D/A1-2 control cells (0.8 and 1.2%, respectively), sup-
porting the idea that GR interferes with PR-mediated cell
dedifferentiation.
GR and PR share many genomic binding regions
To explore potential mechanisms involved in the GR in-
hibitory effect on PR activity, we characterized PR and
GR binding by chromatin immunoprecipitation coupled
with deep sequencing (ChIP-seq) upon treatment with
their respective hormones (PR-R5020 and GR-DEX) in
T47D/A1-2 cells. We performed deep sequence coverage for
all experiments (Supplementary Table S1) and called peaks
using a stringent P-value cutoff (1E-10) to ensure high con-
fidence in the identification of GR and PR binding sites.
Consistent with previous reports (13,54–57), our data
showed that most of the GR and PR binding events (>95%)
depend on hormone activation, (Supplementary Table S1).
In fact, we found many more binding events for PR than
for GR (28 563 and 10 640 respectively) upon 1 h treatment
with their specific hormones. Of note, most PR binding
events (23 602, i.e. >80%) in T47D/A1-2 cells correspond
to PR R5020 binding sites identified in T47D-WT cells (57).
Moreover, an important fraction of the GR binding regions
upon DEX treatment (>88%) mapped to regions that were
also bound by PR upon R5020 stimulation in T47D/A1-
2. Consistently, almost half of the activated PR binding re-
gions (>32%) were also bound by the GR upon DEX treat-
ment. Taken together, these results prompted us to iden-
tify and define ‘GR enriched’, ‘PR enriched’ and ‘PR-GR
shared’ genomic regions in T47D/A1-2 cells, as those sites
that present only GR or PR ChIP-seq signal, or both. As de-
picted in the heatmap of Figure 2A, the GR clearly bound
to GR enriched regions while the PR was largely absent at
these sites in both T47D/A1-2 and WT cells. Conversely,
PR bound to PR enriched regions in both epithelial mam-
mary cell types, while there was no signal from the GR
ChIP-seq in the vicinity of these regions. At last, both GR
and PR bound to the PR-GR shared regions. Noteworthy,
the PR ChIP-seq signal profiled in T47D/A1-2 cells was
faithfully recapitulated by the PR ChIP-seq performed in
T47D-WT cells, further reinforcing the suitability of the
T47D/A1-2 as model to study the GR effects in the T47D
breast cancer cells.
De novo motif analyses showed that both PR and GR
bound to their known DNA-binding motif upon stimula-
tion with their respective hormones (Supplementary Figure
S3A). These binding motifs are almost the same for both
receptors, thus accounting for the large amount of shared
binding sites in T47D/A1-2 cells. Also, several of the sig-
nificantly co-enriched motifs were shared between GR and
PR binding sites, although present at different proportions
(e.g. AR-halfsite, FOX and AP-like motifs, Supplementary
Figure S3A).
To gain further insights into the DNA-binding motifs
specifically enriched in the non-shared receptor binding re-
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Figure 1. GR interferes with progestin-induced cell proliferation and dedifferentiation. (A and B) Cell proliferation was evaluated by using ELISA BrdU
colorimetric assay (Roche) in T47D-WT (GRlow) and T47D/A1-2 (GRhigh) growing cells incubated with R5020 10 nM, DEX 10 nM or both hormones.
(A) Cells were harvested at 14 h (upper panel) or 18 h (lower panel) after hormone treatment. (B) Previous to hormone treatment, cells were transfected
with control (Ctrol) or GR siRNAs. GR expression was analyzed by western blotting using a specific GR antibody (upper panel). Values are expressed
as percentage of increased proliferation relative to untreated cells (Control). Means ± S.D. from five independent experiments are shown. ***, P ≤ 0.001;
**, P ≤ 0.01; *, P ≤ 0.05. (C and D) T47D-WT and T47D/A1-2 cells were treated with R5020 10 nM (C and D) or/and DEX 10 nM (D). After 24 h,
cells were harvested and incubated with antibodies against human CD44-APC and CD24-PE and analyzed by flow cytometry. The upper figures show a
representative expression pattern of CD44 and CD24 obtained by FACS. Quadrant 2, Panel 6 (Q2, P6) indicates CD44high/CD24low labeled cells. In the
lower figures values are expressed as percentage of CD44high/CD24low subpopulation. Means ± S.D. from three independent experiments are shown. ***,







 Fac de Agronom
ia user on 10 O
ctober 2019
Nucleic Acids Research, 2019 7
Figure 2. GR and PR share many binding sites. (A) Normalized GR and PR ChIP-seq signals from T47D/A1-2 cells treated for 1 h with DEX 10 nM
(GR DEX) or R5020 10 nM (PR R5020). Data are represented as a heatmap clustered in GR enriched, PR enriched and GR-PR shared binding sites,
centered (±6 Kb) at the GR DEX (for GR enriched regions) or PR R5020 (for PR shared and enriched regions) peaks. The normalized PR ChIP-seq signal
from T47D-WT treated for 1 h with R5020 10 nM is also shown. (B) Selected top de novo-motifs recovered from GR-enriched; PR-enriched and PR-GR
shared binding sites. See Methods for details. (C) Aggregation plots showing GR and PR (with or without hormone treatment, as indicated on the right)
ChIP-seq signal enrichments centered (+/- 3Kb) at the peaks with the highest score (top 10%), as analyzed by the peak finding algorithm (see Methods).
The set of peaks used for each plot corresponds to the ChIP-seq samples indicated in the upper label of each box. As a control, the signal enrichment for
PR-R5020, profiled by ChIP-seq in T47D-WT cells is presented in all plots. The last box shows the aggregation plots obtained for the top 10% PR-R5020
regions profiled in T47D-WT cells.
PR enriched binding sites (i.e. the 1243 GR-DEX regions
that are not bound by the PR upon R5020 stimulation, and
the 19,375 PR-R5020 regions not shared with GR-DEX,
respectively, Figure 2A), and compared them with the 9188
PR/GR shared regions. The global de novo analysis (using
by default random genomic regions to calculate the motif
enrichment) showed that the top motif enriched in the GR
enriched, the PR enriched and the PR-GR shared regions
was highly similar (Figure 2B). There was only one base dif-
ferent with the top motif enriched in the PR enriched re-
gions, which did not present a strong G in the sixth position
upstream the center of the palindrome (Supplementary Fig-
ure S3B). In contrast, co-enriched motifs identified in this
analysis with default settings were largely different for the
GR and PR enriched regions (Figure 2B; Supplementary
Tables S2 and 3).
To gain further insights into the genomic occupancy
of the steroid receptors profiled, we generated aggrega-
tion plots centered at the peaks obtained for the cognate
hormone-stimulated receptor datasets. Results presented
in Supplementary Figure S3C show the average GR (in
T47D/A1-2 cells) and PR ChIP-seq signals (in both T47D-
WT and T47D/A1-2 cells) centered at either the 10 640
GR-DEX (in T47D/A1-2 cells), the 28 563 PR-R5020 (in
T47D/A1-2 cells) or the 43 398 PR-R5020 (in T47D-WT)
peaks. This analysis revealed strong and shared ChIP-seq
signals for the GR-DEX and PR-R5020 at the opposite re-
ceptor peaks (Supplementary Figure S3C). To directly in-
terrogate whether protein occupancy was similarly high at
the strongest regions of the opposite receptor, we restricted
the regions used for the aggregation plots to the top 10%







 Fac de Agronom
ia user on 10 O
ctober 2019
8 Nucleic Acids Research, 2019
or T47D-WT) and GR-DEX signals. These analyses also
revealed that the strongest PR binding sites upon R5020
treatment are indeed strong GR binding sites after DEX
stimulation (Figure 2C).
Most importantly, these results are still valid when us-
ing PR binding sites in T47D-WT cells. Thus, PR and GR
binding sites are largely shared throughout the genome
of T47D/A1-2 cells and present similar occupancy en-
richments at the strongest binding regions, as depicted in
the genome browser screenshot examples of Supplemen-
tary Figure S4A, showing GR and PR binding at sev-
eral inter- and intra-genic regions in the vicinity of se-
lected genes. In particular, we observed such shared bind-
ing sites on some genes known to be regulated by R5020
in T47D-MTVL (WT) (56,58–59) and also involved in ei-
ther epithelial-to-mesenchymal transition and cell differen-
tiation (i.e. STAT5A, ELF5 and SNAI1) (60,61), and cell
cycling/proliferation (i.e. GREB1) (62,63) (Supplementary
Figure S4A).
GR alters PR-mediated transcriptional response in a gluco-
corticoid dependent and independent manner
Given the observation that both PR and GR are bound
to regions located nearby some genes relevant to PR-
downstream activity (Supplementary Figure S4A, red
boxes), we hypothesized that these genes may be tran-
scriptionally modulated by GR. When T47D/A1-2 cells
were incubated with each hormone alone, the expression
of STAT5A, GREB1 and SNAI1 was induced; however,
neither R5020 nor DEX affected ELF5 expression (Fig-
ure 3A). Interestingly, when T47D/A1-2 cells were co-
incubated with both hormones, GR activation by DEX in-
hibited the R5020-dependent induction of STAT5A and
GREB1 (Figure 3A). This negative modulation was not ob-
served on SNAI1 and ELF5 expression, wherein the pres-
ence of DEX potentiated R5020-mediated SNAI1 increase
while downregulating ELF5 transcript levels. At the ge-
nomic level, R5020-dependent PR recruitment to the regu-
latory regions located in the vicinity of STAT5A, ELF5 and
GREB1 significantly diminished when cells were co-treated
with both hormones, while PR binding increased at the
regulatory regions associated with SNAI1 (Figure 3B, left
panel). Oppositely, DEX-dependent GR recruitment to the
same regions was also affected by the presence of the pro-
gestin (Figure 3B, right panel). In fact, R5020 potentiates
binding of the activated GR to regulatory regions associ-
ated with SNAI1 and STAT5A while it hinders GR recruit-
ment to ELF5 and GREB1. Taken together, these results
indicate that GR and PR are able to modulate each other´s
activities upon activation with their cognate hormones. The
functional crosstalk between both receptors would be me-
diated, at least in part, through their recruitment to shared
regulatory regions.
Since GR appears to be sufficient to modulate PR ac-
tivity in the absence of a glucocorticoid stimulus (Figure
1), we wondered whether GR expression could affect the
transcriptional levels of the genes originally selected based
on shared GR-PR binding. Strikingly, STAT5A, GREB1
and SNAI1 genes exhibit a diminished R5020-dependent
transcriptional activity in T47D/A1-2 compared to WT
cells. Conversely, ELF5, which is repressed by R5020, did
not show a significant level of transcriptional repression in
the T47D/A1-2 compared to T47D-WT cells (Figure 3C).
Indeed, depletion of GR by siRNA knockdown restores
the progestin-dependent expression of STAT5A, GREB1,
SNAI1 and ELF5 which reached comparable levels to those
observed in WT cells (Figure 3C). Other relevant genes such
as EGFR and BCL-X, also known to be regulated by pro-
gestins (56,64) exhibited a similar transcriptional activity in
response to R5020 in both cell lines (Supplementary Figure
S4B), pointing to a gene-specific GR-PR modulation.
The crosstalk between GR and PR was not only con-
straint to T47D cells, as similar results were obtained in
MCF-7L, another breast-cancer cell line (Supplementary
Figure S5). These cells, contrary to the original MCF-7, ex-
press endogenous PR and GR independently of ER activ-
ity (65). RT-qPCRs of selected genes show that GR acti-
vation by DEX inhibited the R5020-dependent induction
of STAT5A, SNAI1A and EGFR, wherein the presence of
DEX potentiated R5020-mediated GREB1 and ELF5 in-
crease (Supplementary Figure S5A). On the other hand,
R5020 affects DEX-dependent induction of Bcl-X. These
results were confirmed by depletion of GR by siRNA
knockdown, where the progestin-dependent expression of
those genes was restored in the absence of GR (Supplemen-
tary Figure S5B). Moreover, cell cycle analyses performed
in MCF-7L cells treated for 18 h with R5020 show that the
percentage of cells accumulated in S phase was significantly
higher compared to untreated cells (13.7 ± 0.7% versus 10.2
± 0.3%) (Supplementary Figure S5C). DEX alone did not
affect S phase accumulation (10.3 ± 0.6%) but inhibited
R5020 mediated action (10.9 ± 0.9%). Together, these find-
ings support the idea that both receptors are able to mod-
ulate each other’s activities upon activation with their cog-
nate hormones in breast cancer cells.
The recruitment of PR to the regulatory regions associ-
ated with the selected genes was assessed by ChIP-qPCR
assays. Results show significantly reduced PR recruitment
in T47D/A1-2 cells compared to T47D-WT upon R5020
stimulation in SNAI1 and STAT5A regulatory regions. On
the other hand, we detected no changes in the regions as-
sociated with the ELF5 and GREB1 genes (Figure 3D).
Intriguingly, despite DEX is not affecting PR recruitment
(Supplementary Figure S4C), GR binding to these regu-
latory regions significantly increased in cells treated with
the progestin-alone compared to untreated cells (Figure
3E), hinting at a possible R5020-dependent GR activa-
tion. Collectively, these results support the idea that both
glucocorticoid-bound and glucocorticoid-free GR hinders
PR-mediated transcriptional regulation of a certain sub-
set of genes, either by impairing the recruitment of PR to
those shared regulatory regions, or by affecting unidentified
downstream processes.
GR and PR co-bind at a subset of genomic sites
The above findings led us to hypothesize that GR and PR
may simultaneously co-bind at these regions. To test this
hypothesis, we performed sequential ChIP for the selected
PR/GR binding regions associated with STAT5A, GREB1,
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Figure 3. GR affects PR binding and transcriptional activity of some progestin-response genes. (A) Gene expression changes measured by RT-qPCR for
selected genes in T47D/A1-2 cells untreated (control) or treated with R5020 10 nM, DEX 10 nM or both hormones for 6 h. Values were normalized with
GAPDH expression. Means ± S.D. from three independent experiments performed in duplicate are shown. ***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05. (B)
Chromatin occupancy analysis measured by ChIP-qPCR for selected regions of PR (left panel) and GR (right panel) in T47D/A1-2 cells treated for 1 h
with R5020 10 nM, DEX 10 nM or both hormones. IgG was used as a negative control. Data are presented as percent input and histograms show the
mean ± S.D. of three experiments performed in duplicate. ***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05. (C) Gene expression changes measured by RT-qPCR
for selected genes in T47D-WT and T47D/A1-2 cells transfected with control (Ctrol) or GR siRNAs and then treated with R5020 10 nM for 6 h. Means ±
S.D. from three independent experiments performed in duplicate are shown. ***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05. (D) Chromatin occupancy analysis
measured by ChIP-qPCR for selected regions of PR in T47D/A1-2 and T47D-WT cells treated for 1 h with R5020 10 nM. IgG was used as a negative
control. Data are presented as percent input and the histograms show the mean ± S.D. of three experiments performed in duplicate. ***, P ≤ 0.001; n.s.:
not significant. R: R5020. (E) Chromatin occupancy analysis measured by ChIP-qPCR for selected regions of GR in T47D-WT and T47D/A1-2 cells
treated for 1 h with R5020 10 nM. IgG was used as a negative control. Data are presented as percent input and the histograms show the mean ± S.D. of
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R5020 is sufficient to trigger GR and PR co-binding at these
regions (Figure 4). Co-stimulation with both hormones fur-
ther increased GR/PR co-recruitment at all loci, except at
STAT5A. Sequential ChIP analysis performed in regions
containing PR enriched binding sites (i.e. regions associ-
ated with HES2 and IGFBP5 genes, Supplementary Fig-
ure S6) did not evidence PR/GR co-recruitment after the
exposure of R5020 alone or R5020 plus DEX (Figure 4).
Taken together, these results indicate that GR binding is
mainly directed to regions that are also targets of the PR
upon R5020 stimulation. Moreover, for a subset of these
regions, increased co-occupation with both receptors is ob-
served upon simultaneous hormone treatment, suggesting
that the activated GR and PR integrate the same protein
complex. Although only explored at selected regions, in this
work we predict co-binding could occur at many genomic
loci given the large fraction of PR and GR shared binding
regions (Figure 2).
GR and PR can be part of the same complex
Bearing in mind previous reports showing steroid receptors
ability to interact with each other (66–68), we sought to
evaluate whether GR could physically interact with PR. To
identify a potential association between GR and PR in the
presence or in the absence of hormones, we performed Co-
IP experiments using PR or GR specific antibodies from
nuclear extracts of T47D/A1-2 cells treated with both ag-
onists. Our results indicated that both PR and GR co-
precipitate after 1 h treatment with R5020 and DEX (Figure
5A, compare IP PR: control (-) versus R5020+DEX).
To directly evaluate GR and PR interactions in living
cells, we run imaging and fluorescence fluctuation cross-
correlation experiments (37) by co-transfecting T47D-WT
cells with peEGFP-PR (35) and pmCherry-GR (36) expres-
sion vectors. Figure 5B displays representative images of
these cells (left panel) and shows the intensity ratios between
the nucleus and cytoplasm for each receptor (right panel).
Non-stimulated PR mainly localizes to the nucleus and GR
mostly distributes in the cytoplasm, while nuclear localiza-
tion of both receptors significantly increases upon 30 min
stimulation with their respective hormones. We did not ob-
serve GR nuclear translocation after R5020 10 nM stimu-
lation.
Analysis of intensity fluctuations showed no cross-
correlation (cross-brightness [Bcc] = 0) in cells expressing
eGFP and mCherry (Figure 5C), as expected from the ab-
sence of interaction between these two molecules. We ob-
tained similar results with cells expressing eGFP-PR and
mCherry or mCherry-GR and eGFP (Figure 5C), where
interaction was also not expected. Cells transfected with
mCherry-GR and eGFP-PR also showed a mean Bcc value
that did not differ from that obtained in cells expressing
eGFP and mCherry, when untreated or treated with ei-
ther hormone (Figure 5C). Nevertheless, and crucially, cells
treated with both hormones simultaneously showed a pos-
itive and significantly greater mean Bcc value (Figure 5C),
suggesting the presence of protein-complexes containing
both activated receptors. Taken together these results indi-
cate that both receptors can be part of the same complex in
living breast cancer cells.
GR mapping upon R5020 stimulation reveals an unexpected
pattern of binding sites
The results presented in the previous sections showed that,
in the absence of glucocorticoids and upon R5020 stimula-
tion, GR expression interferes with the recruitment of PR
to certain GR/PR shared regions, affecting PR-mediated
gene expression regulation. To gain insights into the po-
tential mechanisms involved, we profiled by ChIP-seq the
genome-wide binding pattern of GR in T47D/A1-2 cells
treated with R5020 alone (Figure 6). We found a total of
633 consistent binding regions between replicates, wherein
almost half are also bound by GR and/or PR upon stimu-
lation with their corresponding hormones (Figure 6A). The
other half (321 peaks) are not bound by GR or PR in ei-
ther non-stimulated cells or in cells stimulated with the cog-
nate hormone for each receptor (Figure 6A). Thus, these
regions are GR unique binding sites that appear selectively
upon R5020 stimulation. We refer hereon to these regions
as ‘GR R5020 unique’.
In agreement with these observations, the regions bound
by GR upon R5020 treatment are moderately enriched for
GR and PR occupancy upon stimulation with DEX or
R5020, respectively, as depicted by the corresponding nor-
malized ChIP-seq signals (Supplementary Figure S7A). Fo-
cusing on the receptor enrichments at the top 10% regions
with higher occupancy for each of the GR and PR datasets
analyzed in this study, we found that while there was exten-
sive co-enrichment of PR and GR occupancy upon stimu-
lation with their respective hormones, this was not the case
at the GR R5020-bound regions (Figure 6B). Thus, highly
occupied regions by GR upon R5020 treatment are neither
enriched in signal from the GR-DEX or PR-R5020 (Fig-
ure 6B). These results indicate that, unexpectedly, novel and
highly occupied GR binding regions appear after R5020
treatment. These are genomic sites that are not occupied by
either activated GR or PR upon cell treatment with their
corresponding hormones.
R5020 treatment drives novel GR recruitment to unique ge-
nomic regions
To further explore the reasons for differential binding of
GR upon R5020 treatment, we performed de novo motif
analysis on these set of regions. Unexpectedly, the top de
novo motif recovered when analyzing all the GR R5020
peaks was REL and not the GR motif (Supplementary Fig-
ure S7B and Table S4). The GR motif itself was not signif-
icant enrichment in this analysis. In fact, constraining the
de novo motif analysis using the GR R5020 unique regions
(i.e. those that were not bound by GR or PR in the other
datasets profiled in this study, Figure 6A) did not change the
results (Figure 6C; Supplementary Figure S7C and Table
S5).The GR motif was, again, not enriched in this dataset.
Conversely, the GR motif was significant enriched and was
recovered as the top result when the de novo motif analysis
was performed in the complementary GR R5020 regions
(i.e. the 312 regions that are not GR R5020 unique, Figure
6A and Supplementary Table S6). Taken together, these re-
sults suggest that GR-binding at the GR-R5020 unique re-
gions occurs tethered to other proteins that would recognize
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Figure 4. PR and GR can simultaneously bind the same chromatin binding sites. Sequential ChIP-qPCR analysis (measured by PR followed by GR ChIP
for selected regions) in T47D/A1-2 cells treated 1 h with R5020 10 nM or R5020 plus DEX 10 nM. IgG was used as a negative control. Data are presented
as percent input (upper panel). Histograms show the mean ± S.D. of three experiments performed in duplicate. ***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05.
Bottom panels show the results in agarose gel of one representative experiment.
Alternatively, it could also suggest direct binding to these
motifs, as recently reported (70). To gain further insights
into these findings, we directly interrogated all the GR and
PR datasets used in this study for enrichments of the two
top de novo motifs recovered from GR R5020 unique re-
gions. Interestingly, the REL and FOXH1 motifs were only
enriched in the GR R5020 regions (Figure 6D). Taken to-
gether, these results suggest a novel mechanism for GR in-
terference with the PR pathway in which R5020 treatment
drives novel GR tethering/direct binding to unique genomic
regions, otherwise not bound by the GR, which could po-
tentially be co-bound by REL and FOXH1 proteins.
We, at last focused in the GR R5020 unique binding sites
that contain REL motifs (82 regions). A gene ontology
analysis of the nearby genes revealed a significant enrich-
ment for proteins involved in the SWI/SNF and other chro-
matin remodeler complexes (Figure 6E). Such genes, encod-
ing for well-known chromatin remodelers as SMARCD2,
ARID1A and INO80C, did present clear GR R5020 peaks
at their promoter and/or enhancer associated regions that
were not otherwise bound by the GR or the PR in any of
the tested conditions (Figure 6F). This receptor-selective
binding profile was further validated by ChIP-qPCR, in
which we detected binding of GR without co-binding of
PR at SMARCD2, ARID1A and INO80C regions (Sup-
plementary Figure S7C-D). The expression of SMARCD2
and ARID1A genes was increased in T47D-WT but not in
T47D/A1-2 cells when treated with R5020 (Figure 6G). In
contrast, the expression of INO80C was not modified after
12 h of treatment with R5020 in T47D-WT cells. However,
it was inhibited in T47D/A1-2 cells. Depletion of GR by







 Fac de Agronom
ia user on 10 O
ctober 2019
12 Nucleic Acids Research, 2019
Figure 5. PR and GR can be part of the same complex. (A) Nuclear extracts from T47D/A1-2 cells treated or not with R5020 10 nM and DEX 10 nM
for 1 h were immunoprecipitated with -PR specific antibody. Rabbit IgG was used as a negative control (IgG). The immunoprecipitates (IP) and inputs
lysates were analyzed by western blotting with -GR or -PR as indicated. Blots correspond to one representative from three independent experiments.
(B and C) T47D-WT cells transiently expressing mCherry-GR and GFP-PR were treated with R5020 10 nM and/or DEX 10 nM for 1 h and imaged by
confocal microscopy. (B) Subcellular distribution of mCherry-GR and GFP-PR in each condition. Representative cells are shown (Scale bar: 7 m) (left
panel). Fluorescence intensity ratios between nucleus and cytoplasm for each receptor in the indicated conditions are shown (right panels). ***, P ≤ 0.001;
**, P ≤ 0.01. (C) Cross-correlation analysis of the fluorescence fluctuations was performed. A scatter plot with the mean ± S.E.M. of the cross-brightness
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Figure 6. GR can bind an unexpected and unique pattern of binding sites after R5020 stimulation. (A) Normalized GR and PR binding ChIP-seq signals
from T47D/A1-2 and T47D-WT cells treated for 1 h with R5020 (GR R5020, PR R5020) or DEX (GR DEX), as indicated by the top labels, is represented
as a heatmap clustered in GR R5020 unique and GR R5020 shared binding sites, centered (±6 Kb) at the GR R5020 peaks. (B) Aggregation plots showing
GR and PR (with or without cognate hormone treatment, as well as GR-R5020) ChIP-seq signal enrichments centered (±3 Kb) at the peaks with the
highest score (top 10%), as analyzed by the peak finding algorithm (see ‘Materials and Methods’ section). The set of peaks used for each plot corresponds
to the ChIP-seq samples indicated in the upper label of each box. As a control, the signal enrichment for PR-R5020, profiled by ChIP-seq in T47D-WT
cells, is presented in all plots. The last box shows the aggregation plots obtained for the top 10% PR-R5020 regions profiled in T47D-WT cells. (C) Top de
novo–motifs recovered from GR R5020 unique binding sites revealed a strong enrichment for REL and FOXH1 recognition motifs. (D) Direct interrogation
for the presence of these motifs performed on all the datasets presented in this study, revealed that REL and FOXH1 motifs were exclusively enriched in
GR-R5020 regions. See ‘Materials and Methods’ section for details. (E) Gene ontology analysis of the GR R5020 unique regions with REL motifs revealed
enrichments for genes associated with chromatin remodeling complexes. (F) PR and GR binding profiles for the indicated samples in the vicinity of the
SMARCD2, ARID1A and INO80C genes. Red boxes show the nuclear receptor binding site validated by ChIP. (G) Gene expression changes (measured
by RT-qPCR for selected genes) induced by R5020 10 nM for 1, 6 and 12 h in T47D-WT and T47D/A1-2 cells transfected with control (Ctrol) or GR
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scriptional activity of these genes (Figure 6G). Taken to-
gether, this provocative finding suggests that upon R5020
addition the GR is able to bind novel, unique genomic re-
gions not bound otherwise by GR upon stimulation with
its cognate hormone. These exclusive binding events could
involve a direct interaction of the receptor to the DNA or be
facilitated by GR tethering to other transcription factors.
DISCUSSION
In a physiological context, cells are contained in a complex
environment and are bathed by a composite milieu where
different hormones and nutrients coexist. Hence, the cellu-
lar response that evolves after the hormonal intake derives
from multiple and simultaneous activation of hormone re-
ceptors which can mutually influence each other. In fact,
functional crosstalk among different steroid receptors that
participate in the development and the differentiation of the
mammary gland has been widely proposed (1,14,16) but the
molecular mechanisms associated with these receptor cross-
actions are still poorly understood.
In this study, we assessed the crosstalk between PR and
GR pathways in a human breast cancer cell line (T47D/A1-
2) that co-expresses similar levels of both functional recep-
tors. When GR is activated with DEX, progestin-dependent
cell cycling/proliferation is completely abrogated (Figure
1). These results complement those from Wan & Nordeen
carried out in the same cell line (25) and are similar to those
observed in MCF-7 cells (12).
Invaluable information provided by global genomic stud-
ies achieved on the functionality of these receptors has
been accumulated during the last decade (38,56,71). For ex-
ample, Wan and Nordeen compared glucocorticoid- and
progestin-regulated gene expression in T47D/A1-2 cells
(25). Their global analysis revealed that the two hormones
separately regulate many common genes, including some
which are differentially regulated. In fact, the differentially
regulated group was almost as large as the set of genes regu-
lated by both hormones. These observations are consistent
with the results from our ChIP-seq experiments performed
in cells treated with either R5020 or DEX alone (Figure 2),
in which an important fraction of GR binding regions is
shared with the PR, and they both show enrichments for
known and common DNA-binding motifs (Supplementary
Figure S3). This suggests that in cells treated with both hor-
mones, PR and GR would have the ability to either displace
each other or to be recruited directly and simultaneously to
the same receptor binding site.
The genes studied in our experimental model were previ-
ously identified as PR-target genes in other systems (56,58–
63). Interestingly, we found shared PR/GR binding sites
nearby these genes (Figure 3). We therefore used this set
of potential enhancers as a proxy to identify the mecha-
nisms involved in GR-mediated inhibition of PR action.
ChIP-qPCR results revealed a complex gene-specific effect.
For SNAI1, both GR and PR independently bind to the
promoter region and consistently, both receptors increase
SNAI1 transcription. Interestingly, co-activation, and at
least a fraction of co-binding promotes a synergistic effect
on both binding and mRNA levels (Figures 3 and 4). On the
other hand, GR inhibits PR-dependent STAT5A expression
at least partially by decreasing PR binding to the putative
enhancer (Figure 3). A similar transcriptional effect is ob-
served in GREB1, however, both GR and PR decrease their
binding at the shared sites. Together, these examples illus-
trate the complexity of the crosstalk at the genomic level.
The role of steroid receptors crosstalk in cancer is be-
coming increasingly relevant (72), although the mechanisms
involved are still a matter of debate. For example, het-
erodimerization has been proposed for GR–ER (11,13,73);
GR-MR (74) and GR–AR (75). Other mechanisms beyond
protein–protein complex formation involves assisted load-
ing (76), where dynamic binding of one receptor can lead
to more accessible chromatin, allowing access of the second
receptor, resulting in additional chromatin remodeling and
recruitment of additional transcription factors that can reg-
ulate cooperative gene expression, as in the case of GR as-
sisting ER binding in mammary cells (13,14). Our data from
co-immunoprecipitation assays and cross-correlation anal-
ysis in living cells (Figure 5) suggest that GR and PR can
form part of the same complex, although a direct physical
interaction has yet to be confirmed. Since higher oligomer-
ization states have been described for both PR and GR
(18), we propose that these receptors can form transcrip-
tional active heterocomplexes. Several questions arise from
this hypothesis: Are GR–PR complexes able to bind PR-
or GR-specific response elements? Do these heterocom-
plexes affect the dynamics of recruitment of each recep-
tor to their sequence-specific DNA binding sites and con-
sequently modulate each other´s transcriptional activity?
How would the transcription outcome be affected when
PR–GR heterocomplexes are recruited to those sites in-
stead of GR–GR or PR–PR homo-oligomers? Particularly,
at specific regions associated with the above-mentioned
progestin–target genes, sequential ChIPs performed upon
co-stimulation showed that both activated receptors bind
simultaneously to these genomic sites (Figure 4), support-
ing the existence of PR–GR heterocomplexes. The capa-
bility of these PR–GR complexes to regulate gene expres-
sion would depend on their target gene context. In fact,
GR activation by DEX inhibited STAT5A and GREB1 but
increased SNAI1 and ELF5 R5020-dependent gene regu-
lation in T47D/A1-2 cells while in MCF-7L, DEX treat-
ment inhibited R5020-dependent expression of STAT5A;
SNAI1 and EGFR but increased GREB1 and ELF5. Thus
our findings suggest a different transcriptional outcome for
PR-GR compared with PR–PR complexes in breast can-
cer cells. Differences in the gene expression outcome could
be due to distinct epigenetic states at the receptor’s binding
sites.
Surprisingly, we also observed that the presence of GR,
even in the absence of glucocorticoids, decreased progestin-
dependent cell proliferation (Figure 1). This effect seems
to occur at the genomic level, as PR binding is reduced
at some enhancers (Figure 3). Since GR in the absence of
ligand has almost no biological activity, we hypothesized
that R5020 could modulate the GR, most likely activat-
ing the receptor (77). In fact, GR ChIP-seq of cells treated
with R5020-only revealed an intriguing binding profile, with
slightly more than six hundred peaks identified with high
confidence (Supplementary Figure S7). These binding re-
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tifs, while these motifs are absent in GR or PR activated
with their respective hormones. Such novel GR-binding
profile could be mediated by other factors that might in-
clude NFB-like transcription factors, since PR was not re-
cruited to those regions. In this sense, among the different
mechanisms that explain the functional crosstalk between
the GR and NF-B signaling pathways (69), a physical in-
teraction between GR and NF-B p65 subunit could medi-
ate GR recruitment to REL motifs. Alternatively, it was re-
cently suggested that GR can bind directly to -B response
elements to repress gene expression (70).
Gene ontology analysis of the genes associated to GR
R5020 unique binding sites containing REL motifs re-
vealed a significant enrichment for proteins involved in the
SWI/SNF and other chromatin remodeler complexes. In-
deed, the expression genes associated with these remod-
eler complexes, such as SMARCD2, ARID1A and INO80C,
was inhibited in response to R5020 in cells expressing
GR (Figure 6). We therefore suggest a potential second-
target effect of GR on PR activity, where progestins––via
GR––modulate the amount of chromatin remodeler’s avail-
ability.
In conclusion, GR negatively modulates PR activity
through at least two independent mechanisms, depending
on which hormones are present in the system. First, in the
absence of glucocorticoids, R5020 activates both PR and
GR. This, nevertheless, would trigger PR binding to ∼28
500 sites and only ∼630 peaks for GR, half of which are
shared with PR. The small number of GR binding sites may
be explained by the low amount of GR molecules in the
nucleus, as R5020 10 nM failed to induce translocation of
the receptor (Figure 2B). We therefore propose that a re-
distribution of the nuclear pool of GR molecules are re-
cruited to these new binding sites. Some of these shared sites
may contain GR/PR complexes (as in SNAI1 and STAT5A
enhancers) and ultimately lead to a decrease in PR bind-
ing. However, this is not a general mechanism, as some co-
binding events do not affect PR binding (as in ELF5 and
GREB1). The GR-R5020 unique sites are not enriched in
canonical GREs, suggesting alternative modes of action.
Our data points to REL as a candidate transcription fac-
tor, however, further experiments are needed to confirm this
hypothesis. GR–R5020-dependent binding produces tran-
scriptional regulation, as observed in the expression of sev-
eral chromatin remodelers. These findings open the possi-
bility of another type of regulation of GR function and
reveal a potential pharmacological interest of the R5020–
GR complex. Second, in the presence of DEX and R5020,
GR–DEX complexes most likely take over the GR–R5020
complexes and hence the modulation of PR activity by GR
would be different. GR–DEX complexes bind many more
sites than GR–R5020 and many regions are shared between
GR and PR, which are in general enriched in hormone re-
sponsive elements. We detected an increase in PR-GR inter-
action both in the nucleoplasm and at individual loci. Taken
together, the heterogeneity in the behavior at specific regula-
tory regions could contribute to an overall reduction in PR
activity, evidenced by cell proliferation and differentiation
assays.
Steroid receptors are among the most promising targets
for translational research. An overwhelming majority of
past work investigating hormone-driven cancers have been
focused on individual receptors and single hormone treat-
ment conditions. Although this has allowed us to under-
stand steroid receptor function, physiologically, we need
to take into account multiple stimuli (78). In this sense,
the study of the steroid receptor interactions in hormone-
dependent cancers is particularly relevant. Here, we ex-
plored different potential mechanisms wherein GR affect
PR activity after progestin´s treatment both in the absence
and in the presence of DEX, a glucocorticoid widely used as
palliative in different breast cancer therapies. Although the
exact role of these mechanisms requires further investiga-
tion, understanding this crosstalk could explain the better
prognosis of PR+/ER+/GR+ breast tumors and may con-
tribute to the development of new endocrine combined ther-
apies.
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